Although immunosuppressive treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis results in a 10-year survival rate of 60–90%, a substantial number of patients suffer ...

Use of mycophenolate mofetil in ANCA-associated vasculitis has been evaluated only in small, noncontrolled cohort studies which were neither powered nor designed to demonstrate efficacy in the ...

Avacopan treatment for vasculitis patients shows a significant risk of liver injury, especially in older and low-weight ...

[69] The impact of antineutrophil cytoplasmic antibody (ANCA)-related vasculitis on pregnancy outcomes will depend on the activity and long-term organ damage, with preeclampsia and prematurity ...

The PEXIVAS trial demonstrated that a reduced-dose glucocorticoid regimen was noninferior to standard dosing in terms of death or end-stage kidney disease in ANCA-associated vasculitis.

UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavneos ...